Head to head
MOTS-c vs Tesofensine
A comparison decided mostly by evidence: Tesofensine has been studied in people to a degree the other has not.
Verdict
Tesofensine rests on firmer evidence
What you are actually choosing between
Both are classed here as metabolic compounds, so this is a within-class choice: the mechanism is broadly shared and what separates them is kinetics, route, and how much has actually been tested.
The overlap is fat loss. On this site's goal weighting — an editorial priority score, not a measure of effect size — MOTS-c rates 4/5 for fat loss and Tesofensine rates 4/5. Outside that overlap they diverge: MOTS-c also carries weight for metabolic health and longevity, Tesofensine for appetite control.
The evidence
This is the part that decides most of it. Tesofensine has approval from a regulator somewhere, though not a current FDA or EMA label — approved in Mexico at 0.5 mg; the 1 mg arm was clearly worse tolerated. MOTS-c has some human data, but it is small, old, or uncontrolled — the human data is observational, not interventional. That gap is the headline, and it is a statement about the literature rather than a promise about you: a compound with trial data can still do nothing for your case, and one without it is unproven rather than disproven.
How they differ in practice
MOTS-c is a subcutaneous injection; Tesofensine is taken by mouth. That is the difference most people actually feel: MOTS-c means reconstituting a vial and injecting; Tesofensine does not require either. If needles are the deciding factor, this line settles it before any of the rest matters.
Tesofensine has a characterized half-life of 9.2 days; MOTS-c does not have one published here at all. That asymmetry is worth more than it looks — it usually tracks how much formal pharmacology has been done on a compound.
Committed time differs: MOTS-c runs 8 weeks, Tesofensine runs 24 weeks.
Source notes
What the evidence actually says
Verbatim, so you can check the verdict above against what it was built from.
MOTS-c
A 16-amino-acid mitochondrial-derived peptide encoded within the mitochondrial 12S rRNA gene. Mechanistically it is linked to AMPK activation and the folate / one-carbon pathway. The strong data are preclinical: injected MOTS-c improved insulin sensitivity, reduced diet-induced obesity and improved physical capacity in mice, including in aged animals. Human data is limited and mostly observational rather than interventional — circulating MOTS-c levels have been measured in relation to exercise, age, insulin resistance and a longevity-associated mitochondrial variant, but there is no established human dosing trial and no approved product. The figures here are compounding-pharmacy and community convention scaled off the 10 mg vial that is the usual market size, not trial-derived doses. The starting point is 2.5 mg twice a week; 5 mg once a week is the same weekly total and is run the same way. Vendor guides also describe a daily 0.5-1 mg microdose pattern, which reaches comparable weekly exposure by a different route. Human half-life has not been characterized, so it is left null rather than estimated.
Tesofensine
An oral triple monoamine (noradrenaline, dopamine, serotonin) reuptake inhibitor, not a peptide. A 24-week randomized phase 2 obesity trial tested 0.25, 0.5 and 1.0 mg daily; 0.5 mg is the dose carried forward and the strength approved in Mexico. It is NOT FDA or EMA approved. The 1.0 mg arm produced clearly more cardiovascular and psychiatric adverse effects, so the upper end of this range is documented but not recommended. Values here are capsule strengths in mg, not vial sizes, and the reconstitution fields do not apply to an oral drug.
Side by side
The numbers
| Attribute | MOTS-c | Tesofensine |
|---|---|---|
| Class | Metabolic | Metabolic |
| Routes | Subcutaneous | Oral |
| Dose range | 2.5 mg–5 mg (typical 2.5 mg) | 250 mcg–1 mg (typical 500 mcg) |
| Frequency | Twice a week | Once daily |
| Half-life | Not characterized | 9.2 days |
| Cycle length | 8 weeks | 24 weeks |
| Experience | Advanced | Advanced |
| Evidence | Limited human data | Approved elsewhere |
| Contraindications |
|
|
| Side effects |
|
|
Turn a typical dose into a mark on the syringe: MOTS-c
Goals
Where they overlap, and where they do not
| Goal | MOTS-c | Tesofensine |
|---|---|---|
| fat loss | MOTS-c: 4/5 | Tesofensine: 4/5 |
| appetite controlone only | MOTS-c: — | Tesofensine: 5/5 |
| metabolic healthone only | MOTS-c: 5/5 | Tesofensine: — |
| longevityone only | MOTS-c: 4/5 | Tesofensine: — |
| muscle growthone only | MOTS-c: 2/5 | Tesofensine: — |
| recovery and sleepone only | MOTS-c: 2/5 | Tesofensine: — |
They overlap on 1 goal and diverge on 5. Weights are this site’s editorial priority score out of 5 — how central a goal is to why people use a compound. They are not effect sizes and two 5s do not mean two equal results.
Next
Go deeper
Related
Other comparisons with these two
Educational information only, not medical advice. Talk to a licensed clinician before starting, changing, or stopping anything.